fingolimod hydrochloride - Profile

What are the generic drug sources for fingolimod hydrochloride and what is the scope of freedom to operate?

Fingolimod hydrochloride is the generic ingredient in two branded drugs marketed by Accord Hlthcare, Alkem Labs Ltd, Apotex, Aurobindo Pharma Ltd, Biocon Ltd, Bionpharma, Chartwell Rx, Dr Reddys, Ezra Ventures, Glenmark Pharms Ltd, Hec Pharm Co Ltd, Hetero Labs Ltd V, Mylan, Prinston Inc, Sun Pharm, Teva Pharms Usa, Zydus Pharms, and Novartis, and is included in nineteen NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Fingolimod hydrochloride has ninety-eight patent family members in thirty-nine countries.

There is one tentative approval for this compound.

Summary for fingolimod hydrochloride

International Patents:	98
US Patents:	2
Tradenames:	2
Applicants:	18
NDAs:	19
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for fingolimod hydrochloride

Generic filers with tentative approvals for FINGOLIMOD HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		EQ 0.5MG BASE	CAPSULE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for FINGOLIMOD HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GILENYA	Capsules	fingolimod hydrochloride	0.25 mg	022527	1	2018-07-19
GILENYA	Capsules	fingolimod hydrochloride	0.5 mg	022527	19	2014-09-22

US Patents and Regulatory Information for fingolimod hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Accord Hlthcare	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	207991-001	Oct 28, 2020	AB	RX	No	No
Alkem Labs Ltd	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	208004-001	Dec 30, 2020	AB	RX	No	No
Apotex	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	207993-001	Dec 18, 2020	AB	RX	No	No
Aurobindo Pharma Ltd	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	207983-001	Feb 28, 2024	AB	RX	No	No
Biocon Ltd	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	207979-001	Dec 4, 2019	AB	RX	No	No
Bionpharma	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	210252-001	May 24, 2023	AB	RX	No	No
Chartwell Rx	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	207971-001	Jun 29, 2020		DISCN	No	No

Expired US Patents for fingolimod hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-001	Sep 21, 2010

International Patents for fingolimod hydrochloride

Country	Patent Number	Title	Estimated Expiration
Morocco	34981	FORMULATIONS COMPRENANT 2-AMINO-2-2-4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DIOL
Russian Federation	2012117561
Colombia	6771459	Formulaciones que comprenden 2-amino-2-[2- (4-octil-fenil)-etil] -propano-1,3-diol
Singapore	10201902152X
South Korea	20140014194	FORMULATIONS COMPRISING 2-AMINO-2-[2-(4-OCTYLPHENYL)ETHYL]PROPANE-1,3-DIOL
Japan	2016155840
Poland	3143990

Supplementary Protection Certificates for fingolimod hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0627406	11C0021	France		PRODUCT NAME: FINGOLIMOD ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES EN PARTICULIER SON CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/11/677/001 20110317
1613288	PA2011010,C1613288	Lithuania		PRODUCT NAME: FINGOLIMODUM; REGISTRATION NO/DATE: EU/1/11/677/001, 2011-03-17 EU/1/11/677/002, 2011-03-17 EU/1/11/677/003, 2011-03-17 EU/1/11/677/004 20110317
1613288	2011/027	Ireland		PRODUCT NAME: GILENYA-FINGOLIMOD; NAT REGISTRATION NO/DATE: EU/1/11/677/001 20110317; FIRST REGISTRATION NO/DATE: EU/1/11/677/002 17/03/2011 IRELAND EU/1/11/677/003 17/03/2011 IRELAND EU/1/11/677/004 20110317
1613288	CR 2011 00023	Denmark		PRODUCT NAME: FINGOLIMOD, HERUNDER FINGOLIMOD SOM HYDROCHLORID; REG. NO/DATE: EU/1/11/677/001-004 20110317
0627406	SPC/GB11/026	United Kingdom		PRODUCT NAME: FINGOLIMOD, I.E. 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DIOL, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/677/001 20110317; UK EU/1/11/677/002 20110317; UK EU/1/11/677/003 20110317; UK EU/1/11/677/004 20110317
0627406	2011020	Ireland		PRODUCT: GILENYA FINGOLIMOD AND/OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF REGISTRATION NO/DATE: IRELAND EU/1/11/677/001, EU/1/11/677/002, EU/1/11/677/003, EU/1/11/677/004 / 17/03/2011; FIRST REGISTRATION NO/DATE: EUROPEAN UNION EU/1/11/677/001, EU/1/11/677/002, EU/1/11/677/003, EU/1/11/677/004 / 17/03/2011
1613288	122011100047	Germany		PRODUCT NAME: FINGOLIMOD ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON; NAT. REGISTRATION NO/DATE: FIRST REGISTRATION: EU EU/1/11/677/001-004 20110317EU/1/11/677/001 EU/1/11/677/002 EU/1/11/677/003 EU/1/11/677/004 20110317

Investment Scenario and Fundamentals Analysis: Fingolimod Hydrochloride

Last updated: February 20, 2026

What Is Fingolimod Hydrochloride?

Fingolimod hydrochloride, marketed as Gilenya (by Novartis), is an oral sphingosine-1-phosphate receptor modulator approved for relapsing forms of multiple sclerosis (MS). It was first approved in the U.S. in 2010. The drug's mechanism involves trapping lymphocytes in lymph nodes, reducing CNS inflammation associated with MS.

Market Overview and Adoption

The global multiple sclerosis drugs market was valued at approximately USD 20 billion in 2022, with fingolimod accounting for roughly 15% sales share [1]. Growth is driven by rising MS prevalence, especially in North America and Europe, aging populations, and a shift toward oral therapies due to patient preference.

Market Penetration and Competition

Fingolimod faces competition from other oral MS agents, including:

• Dimethyl fumarate (Tecfidera)
• Teriflunomide (Aubagio)
• Siponimod (Mayzent)
• Ponesimod (R-CHOP, under development)

Despite competition, fingolimod maintains a leading position due to its established efficacy and safety profile.

Revenue and Sales Trends

In 2022, Novartis reported global sales of Gilenya at approximately USD 4.2 billion [2]. The growth rate from 2018 to 2022 averaged 4% annually. Patent expiry nearing in key markets (e.g., U.S. patent expiration in 2027) raises concerns over revenue erosion, emphasizing the importance of lifecycle management strategies.

Drivers and Risks in Investment

Growth Drivers

• Increasing global prevalence of MS
• Patient preference for oral therapies over injectable drugs
• Potential expansion into early or progressive MS indications
• Generic entry opportunities post-patent expiry

Risks and Challenges

• Patent expiration leading to generic competition
• Safety concerns such as cardiac arrhythmias and infections
• Regulatory challenges in expanding indications
• Market saturation in mature markets

Regulatory and Patent Landscape

Patent protection originally granted in multiple jurisdictions up to 2027, with patent extensions under consideration. Patent cliffs threaten revenue stability, requiring Novartis to innovate or seek new indications.

Clinical Development and Pipeline

Novartis is exploring fingolimod's efficacy in other autoimmune diseases, including psoriasis and inflammatory bowel disease. Early-phase trials are ongoing, but failure risks remain.

Investment Fundamentals

Key Metric	2022 Data	Notes
Global sales	USD 4.2 billion	Driven by MS treatment demand
Patent expiry	2027 (U.S.)	Patent cliffs imminent
Market share	Approximately 15% of the MS market	Competitive landscape tight
R&D investment	USD 1.2 billion (2022)	Focused on pipeline and new indications

Financial Impacts

Sales growth potential hinges on new indications and market penetration. Patent expiration could induce revenue decline unless offset by new formulations or indications.

Competitive Positioning

Fingolimod's older oral formulation provides a foundation but will face commoditization post-patent. The pipeline's success in expanding into new indications or developing next-generation molecules is critical for sustained valuation.

Key Takeaways

• Fingolimod hydrochloride is an established MS therapy with significant revenue in 2022.
• The upcoming patent expirations pose risks for revenue decline; strategic lifecycle management is essential.
• Market growth depends on expanding indications and patient access.
• Competitive landscape is intense, with several alternatives and emerging therapies.
• R&D efforts targeting new autoimmune indications offer potential upside.

FAQs

1. When will generic versions of fingolimod hydrochloride enter the market?
Generic entry is expected after patent expiry, scheduled for 2027 in the U.S. and possibly earlier in other jurisdictions with patent challenges.

2. What are the main side effects associated with fingolimod?
Risks include cardiac arrhythmias, infections, and macular edema. These safety concerns require monitoring during treatment initiation.

3. Are there opportunities for expanding fingolimod’s use?
Yes, clinical trials are investigating its efficacy in other autoimmune conditions, potentially broadening the market.

4. How does fingolimod compare to newer MS therapies?
Fingolimod has a well-established safety and efficacy profile but faces competition from newer agents with more favorable safety profiles or broader indications.

5. What strategic moves can enhance fingolimod’s future value?
Developing next-generation formulations, expanding indications, and portfolio diversification into other autoimmune diseases can mitigate patent risk and sustain revenues.

---

References

[1] Market Research Future. (2023). Multiple sclerosis drugs market report.
[2] Novartis Annual Report. (2022). Financial highlights and product sales.